This is a preview of subscription content, log in via an institution to check access.
Reference
Wei X, et al. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clinical Drug Investigation : 26 Sep 2019. Available from: URL: https://doi.org/10.1007/s40261-019-00842-0
Rights and permissions
About this article
Cite this article
Genotyping for breast cancer endocrine therapy cost effective. PharmacoEcon Outcomes News 838, 12 (2019). https://doi.org/10.1007/s40274-019-6257-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6257-z